altretamine + doxorubicin + vincristine + cytarabine + cyclophosphamide

This is a five-drug **chemotherapy combination** consisting of altretamine (an alkylating-like agent), doxorubicin (an anthracycline antitumor antibiotic), vincristine (a vinca alkaloid), cytarabine (a pyrimidine antimetabolite), and cyclophosphamide (an alkylating agent). These agents work synergistically through distinct mechanisms—primarily DNA damage, inhibition of DNA synthesis and repair, microtubule disruption, and topoisomerase II interference—to target rapidly dividing cancer cells, particularly in hematologic malignancies and solid tumors. No specific branded regimen or developer is associated with this exact combination, which appears non-standard and may be investigational or historical; similar multi-agent regimens like Hyper-CVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with cytarabine + methotrexate) are used for acute lymphoblastic leukemia and lymphomas, but this variant lacks dexamethasone or methotrexate.